Respiratory diseases and muscle dysfunction

Expert Review of Respiratory Medicine

Volumn 6, Issue 1, 2012, Pages 75-90

  Gea, Joaquim ^a   Casadevall, Carme ^a   Pascual, Sergi ^a   Orozco Levi, Mauricio ^a   Barreiro, Esther ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Drugs; Exercise limitation muscle remodeling; Hypoventilation; Inflammation; Limb muscles; Muscle dysfunction; Respiratory diseases; Respiratory muscles

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORIDE ION; CORTICOSTEROID; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM ION; SODIUM ION;

ADVANCED CANCER; AGING; ANGINA PECTORIS; ARTIFICIAL VENTILATION; ASTHMA; BREATHING MECHANICS; BREATHING MUSCLE; CACHEXIA; CARBOHYDRATE METABOLISM; CHLORIDE BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG FIBROSIS; LUNG GAS EXCHANGE; MALNUTRITION; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PHYSICAL ACTIVITY; POTASSIUM BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SCOLIOSIS; SEDENTARY LIFESTYLE; SEPSIS; SIDE EFFECT; SKELETAL MUSCLE; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; SMOKING; SODIUM BLOOD LEVEL; SURVIVAL; THORAX MALFORMATION;

EID: 84856425526     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.81     Document Type: Review

References (209)

1. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N. Engl. J. Med. 337, 1799-1806 (1997). (Pubitemid 28006784)
2. Orozco-Levi M, Gea J, Lloreta J et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur. Respir. J. 13, 371-378 (1999). (Pubitemid 29086836)
3. Orozco-Levi M, Lloreta J, Minguella J, Serrano S, Broquetas J, Gea J. Injury of the human diaphragm associated with exertion and COPD. Am. J. Respir. Crit. Care Med. 164, 1734-1739 (2001).
4. Barreiro E, de la Puente B, Minguella J et al. Oxidative stress and respiratory muscle dysfunction in severe COPD. Am. J. Respir. Crit. Care Med. 171, 1116-1124 (2005). (Pubitemid 40663723)
5. Orozco-Levi M, Gea J, Sauleda J et al. Structure of the latissimus dorsi muscle and respiratory function. J. Appl. Physiol. 78, 1132-1139 (1995).
6. Barreiro E, Ferrer A, Hernández-Frutos N, Palacio J, Broquetas J, Gea J. Expiratory function and cellular properties of the external oblique muscle in patients with extremely severe COPD. Am. J. Crit. Care Med. 159(Suppl.), A588 (1999) (Abstract).
7. Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural and functional changes in the skeletal muscles of COPD patients: The 'Compartments' Theory. Mon. Arch. Chest Dis. 56, 214-224 (2001). (Pubitemid 32951962)
8. Gea J, Barreiro E, Orozco-Levi M. Skeletal muscle adaptation to disease states. In: Skeletal Muscle Plasticity in Health and Disease: From Genes to Whole Muscle. Bottinelli R, Reggiani C (Eds). Springer, Doordrecht, The Netherlands, 315-360 (2006).
9. Coronell C, Orozco-Levi M, Mendez R, Ramirez A, Galdiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur. Respir. J. 24, 129-136 (2004). (Pubitemid 39029078)
10. Hernandez N, Orozco-Levi M, Belalcazar V et al. Dual morphometrical changes of the deltoid muscle in patients with COPD. Respir. Physiol. Neurobiol. 134, 219-229 (2003). (Pubitemid 36349245)
11. Gea J, Pasto M, Carmona M, Orozco-Levi M, Palomeque J, Broquetas J. Metabolic characteristics of the deltoid muscle in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 17, 939-945 (2001). (Pubitemid 32600343)
12. Epstein SK. An overview on respiratory muscle function. Clin. Chest Med. 15, 619-639 (1994).
13. Martyn J, Powell E, Shore S, Emrich J, Engel LA. The role of respiratory muscles in the hyperinflation of bronchial asthma. Am. Rev. Respir. Dis. 121, 441-447 (1980). (Pubitemid 10128963)
14. Appendini L, Purro A, Patessio A et al. Partitioning of inspiratory muscle workload and pressure assistance in ventilatordependent COPD patients. Am. J. Respir. Crit. Care Med. 154, 1301-1309 (1996). (Pubitemid 26391173)
15. Martínez-Llorens J, Ramírez M, Colomina MJ et al. Muscle dysfunction and exercise limitation in adolescent idiopathic scoliosis. Eur. Respir. J. 36, 393-400 (2010).
16. Casaburi R. Skeletal muscle function in COPD. Chest 117, S267-S271 (2000).
17. Noguera A, Sala E, Pons AR, Iglesias J, MacNee W, Agusti AG. Expression of adhesion molecules during apoptosis of circulating neutrophils in COPD. Chest 125, 1837-1842 (2004). (Pubitemid 38648419)
18. Bolton C, Ionescu A, Shiels K et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 1286-1293 (2004). (Pubitemid 39657192)
19. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 347-360 (2003). (Pubitemid 36204553)
20. American Thoracic Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: A statement of the American Thoracic Society and European Respiratory Society. Am. J. Respir. Crit. Care Med. 159, S1-S40 (1999).
21. Swallow EB, Reyes D, Hopkinson NS et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62, 115-120 (2007).
22. Rochester DF, Braun NMT, Arora NS. Respiratory muscle strength in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 119, 151-154 (1979). (Pubitemid 9121306)
23. Similowsky T, Yan S, Gaithier AP, Macklem PT. Contractile properties of the human diaphragm during chronic hyperinflation. N. Engl. J. Med. 325, 917-923 (1991).
24. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 153, 976-980 (1996). (Pubitemid 26081648)
25. Goldman MD, Grassino A, Mead J, Sears A. Mechanics of the human diaphragm during voluntary contraction: Dynamics. J. Appl. Physiol. 44, 840-848 (1978). (Pubitemid 9158225)
26. Macklem PT, Gross D, Grassino GA, Roussos C. Partitioning of inspiratory pressure swings between diaphragm and intercostal/accessory muscles. J. Appl. Physiol. 44, 200-208 (1978). (Pubitemid 9137195)
27. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 150, 1453-1455 (1994). (Pubitemid 24356667)
28. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: Underlying mechanisms and therapy perspectives. Am. J. Clin. Nutr. 71, 1033-1047 (2000). (Pubitemid 30230549)
29. Barreiro E, Gea J, Di Falco M, Kriazhev L, James S, Hussain SN. Protein carbonyl formation in the diaphragm. Am. J. Respir. Mol. Cell Biol. 32, 9-17 (2005). (Pubitemid 40053299)
30. Barreiro E, Peinado VI, Galdiz JB et al. ENIGMA in COPD Project. Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am. J. Respir. Crit. Care Med. 182, 477-488 (2010).
31. Gea J, Pastó M, Ennion S, Goldspink G, Broquetas JM. Expression of the genes corresponding to myosin heavy chain isoforms (MyHC I, IIa and IIx) in the diaphragm of patients suffering from COPD. Eur. Respir. J. 12(Suppl. 28), S267 (1998) (Abstract).
32. Hards JM, Reid WD, Pardy RL, Paré PD. Respiratory muscle morphometry: Correlation with pulmonary function and nutrition. Chest 97, 1037-1044 (1990). (Pubitemid 20166787)
33. Lloreta J, Orozco-Levi M, Gea J, Broquetas J. Selective diaphragmatic mitochondrial abnormalities in a patient with marked airflow obstruction. Ultrastruct. Pathol. 20, 67-71 (1996). (Pubitemid 26049971)
34. Marin-Corral J, Minguella J, Ramírez- Sarmiento AL, Hussain SN, Gea J, Barreiro E. Oxidised proteins and superoxide anion production in the diaphragm of severe COPD patients. Eur. Respir. J. 33, 1309-1319 (2009).
35. Clanton TL, Levine S. Respiratory muscle fiber remodeling in chronic hyperinflation: Dysfunction or adaptation? J. Appl. Physiol. 107, 324-335 (2009).
36. Campbell JA, Hughes RL, Shagal V, Frederiksen J, Shields TW. Alterations in intercostal muscle morphology and biochemistry in patients with chronic obstructive lung disease. Am. Rev. Respir. Dis. 122, 679-686 (1980). (Pubitemid 11194214)
37. Gea J. Myosin gene expression in the respiratory muscles. Eur. Respir. J. 10, 2404-2410 (1997). (Pubitemid 27479568)
38. Jimenez M, Gea J, Aguar MC et al. Capillary density and respiratory function in the external intercostal muscle. Arch. Bronconeumol. 35, 471-476 (1999).
39. Levine S, Nguyen T, Friscia M et al. Parasternal intercostal muscle remodeling in severe chronic obstructive pulmonary disease. J. Appl. Physiol. 101, 1297-1302 (2006).
40. Ramírez-Sarmiento A, Orozco-Levi M, Barreiro E et al. Expiratory muscle endurance in chronic obstructive pulmonary disease. Thorax 57, 132-136 (2002). (Pubitemid 34123886)
41. Arnold JS, Thomas AJ, Kelsen SG. Length-tension relations of abdominal expiratory muscles: Effect of emphysema. J. Appl. Physiol. 62, 739-745 (1987). (Pubitemid 17066637)
42. Dodd DS, Brancatisano T, Engel LA. Chest wall mechanics during exercise in patients with severe chronic airflow obstruction. Am. Rev. Respir. Dis. 129, 33-38 (1984). (Pubitemid 14176498)
43. Ninane V, Rypens F, Yernault J, De Troyer A. Abdominal muscle use during breathing in patients with chronic airflow obstruction. Am. Rev. Respir. Dis. 146, 16-21 (1992).
44. Seymour JM, Spruit MA, Hopkinson NS et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur. Respir. J. 36, 81-88 (2010).
45. Bernard S, LeBlanc P, Whittom F et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158, 629-634 (1998). (Pubitemid 28378196)
46. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am. J. Respir. Crit. Care Med. 52, 2021-2031 (1995).
47. Sala E, Roca J, Marrades RM et al. Effect of endurance training on skeletal muscle bioenergetic in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 159, 1726-1734 (1999). (Pubitemid 29275034)
48. Engelen MP, Schols AM, Does JD, Gosker HR, Deutz NE, Wouters EF. Exerciseinduced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 1697-1704 (2000).
49. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJM. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow obstruction. Am. Rev. Respir. Dis. 146, 935-940 (1992).
50. Eisner MD, Iribarren C, Blanc PD et al. Development of disability in chronic obstructive pulmonary disease: Beyond lung function. Thorax 66, 108-114 (2011).
51. Maltais F, Leblanc P, Simard C et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154, 442-447 (1996). (Pubitemid 26269117)
52. Doucet M, Dubé A, Joanisse DR et al. Atrophy and hypertrophy signalling of the quadriceps and diaphragm in COPD. Thorax 65, 963-970 (2010).
53. O'Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: A systematic review. Chest 136, 1269-1283 (2009).
54. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fiber types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur. Respir. J. 3, 192-196 (1990). (Pubitemid 20066922)
55. Jakobsson P, Jordfelt L, Henriksson J. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 151, 374-377 (1995).
56. Simard C, Maltais F, Leblanc P, Simard PM, Jobin J. Mitochondrial and capillarity changes in vastus lateralis muscle of COPD patients: Electron microscopy study. Med. Sci. Sports Exerc. 28, S95 (1996).
57. Satta A, Migliori GB, Spanevello A et al. Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. Eur. Respir. J. 10, 2853-2860 (1997). (Pubitemid 28052800)
58. Whittom F, Jobin J, Simard PM et al. Histochemical and morphological characteristics of the vastus lateralis muscle in COPD patients. Med. Sci. Sports Exerc. 30, 1467-1474 (1998). (Pubitemid 28465510)
59. Barreiro E, Gea J, Corominas JM, Hussain SN. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 29, 771-778 (2003). (Pubitemid 38045945)
60. Barreiro E, Gea J, Matar G, Hussain SNA. Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of COPD patients. Am. J. Respir. Cell Mol. Biol. 33, 636-642 (2005). (Pubitemid 41753140)
61. Orozco-Levi M, Ferrer MD, Coronell C et al. Evidence of sarcomere disruption and myofibrillar degeneration in the quadriceps muscle of stable COPD patients. Eur. Respir. J. 22(Suppl. 45), S552 (2003) (Abstract).
62. Gea J, Suelves M, Casadevall C, Orozco- Levi M, Barreiro E, Muñoz-Canoves P. Both urokinase-type plasminogen activator (uPA) and uPA receptor are upregulated in respiratory muscles but not in peripheral muscles of severe COPD patients. Proc. Am. Thorac. Soc. 2, A530 (2005) (Abstract).
63. Barreiro E, Schols A, Polkey M et al. On behalf of the ENIGMA in COPD project. Cytokine profile in quadriceps muscles of patients with severe chronic obstructive pulmonary disease. Thorax 63, 100-107 (2008).
64. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernández N, Tálamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur. Respir. J. 26, 390-397 (2005). (Pubitemid 41264199)
65. Sato Y, Asoh T, Honda Y, Fujimatso Y, Higuchi I, Oizumi K. Morphological and histochemical evaluation of biceps muscle in patients with chronic pulmonary emphysema manifesting generalized emaciation. Eur. Neurol. 37, 116-121 (1997). (Pubitemid 27077813)
66. Spruit MA, Gosselink R, Troosters T et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58, 752-756 (2003). (Pubitemid 37094049)
67. Güerri R, Gayete A, Balcells E et al. Mass of intercostal muscles associates with risk of multiple exacerbations in COPD. Respir. Med. 104, 378-388 (2010).
68. Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156, 794-799 (1997). (Pubitemid 27396417)
69. Crul T, Testelmans D, Spruit MA et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol. Biochem. 25, 491-500 (2010).
70. Creutzberg EC, Wouters EF, Vanderhoven- Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 1239-1245 (2000).
71. Crul T, Spruit MA, Gayan-Ramirez G et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur. J. Clin. Invest. 37, 897-904 (2007). (Pubitemid 350029204)
72. Decramer M, Rennard S, Troosters T et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 5, 235-256 (2008).
73. Vilaró J, Ramirez-Sarmiento A, Martínez- Llorens JM et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir. Med. 104, 1896-1902 (2010).
74. Picado C, Fiz JA, Montserrat JM et al. Respiratory and skeletal muscle function in steroid-dependent bronchial asthma. Am. Rev. Respir. Dis. 141, 14-20 (1990). (Pubitemid 20023375)
75. Mancuso CA, Sayles W, Robbins L et al. Barriers and facilitators to healthy physical activity in asthma patients. J. Asthma 43, 137-143 (2006). (Pubitemid 43879429)
76. Gustafson T, Boman K, Rosenhall L, Sandström T, Wester PO. Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Eur. Respir. J. 9, 237-240 (1996). (Pubitemid 26069824)
77. Rochester DF, Arora NS. The respiratory muscles in asthma. In: Diagnostic Aspects and Management of Asthma. Lavietes MH, Reichman LB (Eds). Purdue-Frederick, Norwalk, CO, USA (1981).
78. Mckenzie DK, Gandevia SC. Strength and endurance of inspiratory and limb muscles in asthma. Am. Rev. Respir. Dis. 134, 999-1004 (1986). (Pubitemid 17171661)
79. Peress L, Sybrecht G, Macklem PT. The mechanism of increase in total lung capacity during acute asthma. Am. J. Med. 61, 165-169 (1976).
80. de Bruin PF, Ueki J, Watson A, Pride NB. Size and strength of the respiratory and quadriceps muscles in patients with chronic asthma. Eur. Respir. J. 10, 59-64 (1997). (Pubitemid 27047181)
81. De Troyer A, Wilson TA. Effect of acute inflation on the mechanics of the inspiratory muscles. J. Appl. Physiol. 107, 315-323 (2009).
82. Laviettes MH, Grocela JA, Maniatis T, Potulski F, Ritter AB, Sunderam G. Inspiratory muscle strenght in asthma. Chest 93, 1043-1048 (1988).
83. Lovis C, Mach F, Unger PF, Bouillie M, Chevrolet JC. Elevation of creatine kinase in acute severe asthma is not of cardiac origin. Intensive Care Med. 27, 528-533 (2001). (Pubitemid 32250082)
84. Tsushima K, Koyama S, Ueno M et al. Rhabdomyolysis triggered by an asthmatic attack in a patient with McArdle disease. Intern. Med. 40, 131-134 (2001). (Pubitemid 33665237)
85. Hoffmann M, Bybee K, Accurso V, Somers VK. Sleep apnea and hypertension. Minerva Med. 95, 281-290 (2004). (Pubitemid 39390988)
86. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo. Clin. Proc. 79, 1036-1046 (2004). (Pubitemid 39007025)
87. Yaggi H, Mohsenin V. Obstructive sleep apnoea and stroke. Lancet Neurol. 3, 333-342 (2004). (Pubitemid 38648854)
88. Chien MY, Wu YT, Lee PL, Chang YJ, Yang PC. Inspiratory muscle dysfunction in patients with severe obstructive sleep apnoea. Eur. Respir. J. 35, 373-380 (2010).
89. Chen H, Tang Y. Sleep loss impairs inspiratory muscle endurance. Am. Rev. Respir. Dis. 140, 907-909 (1989). (Pubitemid 19259485)
90. Wåhlin-Larsson B, Kadi F, Ulfberg J, Piehl Aulin K. Skeletal muscle morphology and aerobic capacity in patients with obstructive sleep apnoea syndrome. Respiration 76, 21-27 (2008). (Pubitemid 351914135)
91. Sauleda J, García-Palmer FJ, Tarraga S, Maimó A, Palou A, Agustí AG. Skeletal muscle changes in patients with obstructive sleep apnoea syndrome. Respir. Med. 97, 804-810 (2003). (Pubitemid 36763893)
92. Wåhlin-Larsson B, Ulfberg J, Aulin KP, Kadi F. The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders. Muscle Nerve 40, 556-561 (2009).
93. Garpestad E, Hatayama H, Parker J et al. Stroke volume and cardiac output decrease at termination of obstructive apneas. J. Appl. Physiol. 73, 1743-1748 (1992).
94. Wilcox PG, Paré PD, Road JD, Fleetham JA. Respiratory muscle function during obstructive sleep apnea. Am. Rev. Respir. Dis. 142, 533-539 (1990). (Pubitemid 20292711)
95. Kimoff J, Cheong T, Olha A et al. Mechanisms of apnea termination in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 149, 707-714 (1994).
96. Griggs G, Findley L, Suratt P, Esau S, Wilhoit S, Rochester D. Prolonged relaxation rate of inspiratory muscles in patients with sleep apnea. Am. Rev. Respir. Dis. 140, 706-710 (1989). (Pubitemid 19234317)
97. Aran X, Félez MA, Gea J, Orozco-Levi M, Sauleda J, Broquetas JM. Respiratory muscle force and resistance in patients with SAHS. The effect of using nighttime CPAP. Arch. Bronconeumol. 35, 440-445 (1999).
98. Shepherd KL, Jensen CM, Maddison KJ, Hillman DR, Eastwood PR. Relationship between upper airway and inspiratory pump muscle force in obstructive sleep apnea. Chest 130, 1757-1764 (2006). (Pubitemid 46033430)
99. Barreiro E, Nowinski A, Gea J, Sliwinski P. Oxidative stress in the external intercostal muscles of patients with obstructive sleep apnoea. Thorax 62, 1095-1101 (2007). (Pubitemid 350206205)
100. Sériès F, Côté C, Simoneau JA et al. Physiologic, metabolic, and muscle fiber type characteristics of musculus uvulae in sleep apnea hypopnea syndrome and in snorers. J. Clin. Invest. 95, 20-25 (1995).
101. Sériès F, Côté C, St Pierre S. Dysfunctional mechanical coupling of upper airway tissues in sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 159, 1551-1555 (1999). (Pubitemid 29227868)
102. Sériès FJ, Simoneau SA, St Pierre S, Marc I. Characteristics of the genioglossus and musculus uvulae in sleep apnea hypopnea syndrome and in snorers. Am. J. Respir. Crit. Care Med. 153, 1870-1874 (1996). (Pubitemid 26187913)
103. Carrera M, Barbé F, Sauleda J, Tomás M, Gómez C, Agustí AG. Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am. J. Respir. Crit. Care Med. 159, 1960-1966 (1999). (Pubitemid 29275069)
104. Von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. J. Cachexia Sarcopenia Muscle 1, 1-5 (2010).
105. Dufresne V, Knoop C, Van Muylem A et al. Effect of systemic inflammation on inspiratory and limb muscle strength and bulk in cystic fibrosis. Am. J. Respir. Crit. Care Med. 180, 153-158 (2009).
106. Swallow EB, Barreiro E, Gosker H et al. Quadriceps muscle strength in scoliosis. Eur. Respir. J. 34, 1429-1435 (2009).
107. Gustafson T, Franklin KA, Midgren B, Pehrsson K, Ranstam J, Ström K. Survival of patients with kyphoscoliosis receiving mechanical ventilation or oxygen at home. Chest 130, 1828-1833 (2006) (Pubitemid 46033441)
108. Duiverman ML, Bladder G, Meinesz AF, Wijkstra PJ. Home mechanical ventilatory support in patients with restrictive ventilatory disorders: A 48-year experience. Respir. Med. 100, 56-65 (2006). (Pubitemid 43033380)
109. Meyer FJ, Lossnitzer D, Kristen AV et al. Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 25, 125-130 (2005). (Pubitemid 40207741)
110. Bauer R, Dehnert C, Schoene P et al. Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respir. Med. 101, 2366-2369 (2007). (Pubitemid 47471400)
111. Mainguy V, Maltais F, Saey D et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 65, 113-117 (2010).
112. Barreiro E, Comtois AS, Mohammed S, Lands L, Hussain SNA. Role of heme oxygenases in sepsis-induced diaphragmatic contractile dysfunction and oxidative stress. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L476-L484 (2002). (Pubitemid 34804006)
113. Le Bourdelles G, Viires N, Boczkowski J et al. Effects of mechanical ventilation on diaphragmatic contractile properties in rats. Am. J. Respir. Crit. Care Med. 149, 1539-1544 (1994). (Pubitemid 24175972)
114. Deconinck N, Van Parijs V, Bleeckers- Bleukx G et al. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul. Disord. 8, 186-192 (1998). (Pubitemid 28246115)
115. Polkey MI, Moxham J. Clinical aspects of respiratory muscle dysfunction in the critically ill. Chest 119, 926-939 (2001). (Pubitemid 32197668)
116. Matsubara S, Okada T, Yoshida M. Mitochondrial changes in acute myopathy after treatment of respiratory failure with mechanical ventilation (acute relaxantsteroid myopathy). Acta Neuropathol. 88, 475-478 (1994). (Pubitemid 24331036)
117. Lacomis D, Giuliani M, Van Cott A et al. Acute myopathy of intensive care: Clinical, electromyographic and pathological aspects. Ann. Neurol. 40, 645-654 (1996). (Pubitemid 26357890)
118. Spizer AR, Giancarlo T, Mahler L. Nueromuscular causes of prolonged ventilator dependency. Muscle Nerve 15, 682-686 (1992).
119. Mehta S, Nelson DL, Klinger JR, Buczko GB, Levy MM. Prediction of postextubation work of breathing. Crit. Care Med. 28, 1341-1346 (2000).
120. Blum D, Omlin A, Baracos VE et al.; European Palliative Care Research Collaborative. Cancer cachexia: A systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit. Rev. Oncol. Hematol. 80(1), 114-144 (2011).
121. Evans WJ, Morley JE, Argilés J et al. Cachexia: A new definition. Clin. Nutr. 27, 793-799 (2008).
122. DeWys W. Management of cancer cachexia. Semin. Oncol. 12, 452-460 (1985).
123. Costelli P, Carbó N, Tessitore L et al. Tumour necrosis factor-alpha mediates changes in muscle protein turnover in a cachectic rat tumour model. J. Clin. Invest. 92, 2783-2789 (1993).
124. García-Martínez C, López-Soriano FJ, Argilés JM. Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. Mol. Cell Biochem. 148, 17-23 (1995).
125. Kirchberger M. Excitation and contraction of skeletal muscle. In: Physiological Basis of Medical Practice. West JB (Ed.). Williams & Wilkins, Baltimore, MD, USA, 62-102 (1991).
126. Llovera M, Carbó N, López-Soriano FJ et al. Different cytokines modulate ubiquitin-gene expression in rat skeletal muscle. Cancer Lett. 133, 83-87 (1998). (Pubitemid 29069115)
127. Fortunati N, Manti R, Birocco N et al. Pro-inflammatory cytokines and oxidative stress/ antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol. Rep. 18, 1521-1527 (2007).
128. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 180, 69-74 (2002). (Pubitemid 34242966)
129. Chevari S, Andial T, Benke K, Shtrenger IA, Free radical reactions and cancer, Vopr. Med. Khim. 38, 4-5 (1992).
130. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi-Fanelli F. Prevention and treatment of cancer cachexia: New insights into an old problem. Eur. J. Cancer 42, 31-41 (2006). (Pubitemid 41814530)
131. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 91, S1133-S1137 (2010).
132. Wang Q, Lu JB, Wu B, Hao LY. Expression and clinicopathologic significance of proteolysis-inducing factor in non-small-cell lung cancer: An immunohistochemical analysis. Clin. Lung Cancer 11, 346-351 (2010).
133. Zhang J, Liu Y, Shi J, Larson DF, Watson RR. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp. Biol. Med. 227, 823-829 (2002).
134. Montes de Oca M, Loeb E, Torres SH, De Sanctis J, Hernández N, Tálamo C. Peripheral muscle alterations in non- COPD smokers. Chest 133, 13-18 (2008).
135. Petersen AM, Magkos F, Atherton P et al. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am. J. Physiol. Endocrinol. Metab. 293, E843-E848 (2007). (Pubitemid 47358998)
136. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 65, 930-936 (2010).
137. Gan WQ, Man WQ, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax 59, 574-580 (2004). (Pubitemid 38901515)
138. Nordskog BK, Fields WR, Hellmann GM. Kinetic analysis of cytokine response to cigarette smoke condensate by human endothelial and monocytic cells. Toxicology 212, 87-97 (2005). (Pubitemid 40981966)
139. Borchers MT, Wesselkamper SC, Curull V et al. Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. J. Clin. Invest. 119, 636-649 (2009).
140. Sauleda J, García-Palmer FJ, González G, Palou A, Agustí AG. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am. J. Respir. Crit. Care Med. 161, 32-35 (2000). (Pubitemid 30055899)
141. Gea J, Orozco-Levi M, Barreiro E. Skeletal and respiratory muscle dysfunction in the systemic inflammatory response syndrome associated with COPD. In: COPD as a Systemic Disease. Cazzola M, Stockley RA, Wouters EFM (Eds). Clinical Publishing, Boca Raton, FL, USA (2008).
142. Creutzberg EC, Wouters EF, Vanderhoven- Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 1239-1245 (2000).
143. Flores EA, Bristain BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor /cachectin promotes muscle metabolism in the rat. J. Clin. Invest. 83, 1614-1622 (1989). (Pubitemid 19124117)
144. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer JE. Interaction between corticosterone and tumor necrosis factor simulated protein breakdown in rat skeletal muscle similar to sepsis. Surgery 108, 460-466 (1990). (Pubitemid 20255486)
145. Plant PJ, Brooks D, Faughnan M et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 42, 461-471 (2010).
146. Fermoselle C, Rabinovich R, Ausin P et al. Severe COPD patients exhibit increased muscle proteolysis in their vastus lateralis. Eur. Respir. J. 36(Suppl.), 338s (2010) (Abstract).
147. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: Involvement of muscle myofilaments. Am. J. Respir. Crit. Care Med. 166, 479-484 (2002).
148. Pascual S, Casadevall C, Martínez-Llorens J et al. Functional blockade of TNF-alpha and myogenic differentiation in cells from peripheral muscles of COPD patients. Am. J. Respir. Crit. Care Med. (2011) (In press) (Abstract).
149. Supinski G. Free radical-induced respiratory muscle dysfunction. Mol. Cell Biochem. 179, 99-110 (1998). (Pubitemid 28118845)
150. Gea J, Barreiro E, Orozco-Levi M. Free radicals, cytokines and respiratory muscles in COPD patients. Clin. Pulm. Med. 14, 117-126 (2007). (Pubitemid 46763347)
151. Gosker HR, Bast A, Haenen GR et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir. Med. 99, 118-125 (2005). (Pubitemid 40017395)
152. Barreiro E, Gáldiz JB, Mariñán M, Álvarez FJ, Hussain SN, Gea J. Respiratory loading intensity and diaphragm oxidative stress: N-acetylcysteine effects. J. Appl. Physiol. 100, 555-563 (2006). (Pubitemid 43671608)
153. Schols AM. Nutrition in chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 6, 110-115 (2000).
154. Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin. Chest Med. 21, 753-762 (2000). (Pubitemid 32057591)
155. Coronell C, Orozco-Levi M, Gea J. COPD and body weight in a Mediterranean population. Clin. Nutr. 21, 437 (2002).
156. Schols AM, Creutzberg E, Buurman W, Campfield L, Saris W, Wouters E. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160, 1220-1226 (1999). (Pubitemid 29487462)
157. Schols AM, Buurman W, van den Brekel S et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51, 819-824 (1996). (Pubitemid 26274084)
158. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 1791-1797 (1998).
159. Kelsen SG, Ference M, Kapoor S. Effects of prolonged undernutrition on structure and function of the diaphragm. J. Appl. Physiol. 58, 1354-1359 (1985). (Pubitemid 15033205)
160. Lopes J, Russell DM, Whitwell J, Jeejeebhoy KN. Skeletal muscle function in malnutrition. Am. J. Clin. Nutr. 36, 602-610 (1982). (Pubitemid 13223049)
161. Valente S, Pasciuto G, Bernabei R, Corbo GM. Do we need different treatments for very elderly COPD patients? Respiration 80, 357-368 (2010).
162. Barreiro E, Coronell C, Laviña B, Ramírez- Sarmiento A, Orozco-Levi M, Gea J; PENAM Project. Aging, sex differences, and oxidative stress in human respiratory and limb muscles. Free Radic. Biol. Med. 41, 797-809 (2006). (Pubitemid 44177663)
163. Chua TP, Anker SD, Harrington D, Coats AJ. Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure. Br. Heart J. 74, 381-385 (1995).
164. García-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM; the EFRAM investigators. Risk factors of readmission to hospital for a COPD exacerbation: A prospective study. Thorax 58, 100-105 (2003). (Pubitemid 36182995)
165. Pitta F, Troosters T, Probst VS, Lucas S, Decramer M, Gosselink R. Potential consequences for stable chronic obstructive pulmonary disease patients who do not get the recommended minimum daily amount of physical activity. J. Bras. Pneumol. 32, 301-308 (2006).
166. Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arch. Phys. Med. Rehabil. 86(10), 1979-1985 (2005). (Pubitemid 41423628)
167. Aguar MC, Gea J, Aran X et al. Modifications in diaphragmatic mechanics induced by inhaled CO2 in COPD patients. Arch. Bronconeumol. 29, 226-228 (1993).
168. Gea J, Orozco-Levi M, Aran X, Sauleda J, Aguar MC, Broquetas JM. Acute hypoxemia and respiratory muscles function in COPD patients. Am. Rev. Respir. Dis. 149(Suppl.), A140 (1994) (Abstract).
169. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: Cause, effects, and disease progression. Int. J. Chron. Obstruct. Pulmon. Dis. 6, 199-208 (2011).
170. Pastoris O, Dossena M, Foppa P et al. Modifications by chronic intermittent hypoxia and drug treatment on skeletal muscle metabolism. Neurochem. Res. 20, 143-150 (1995).
171. Romer LM, Haverkamp HC, Amann M, Lovering AT, Pegelow DF, Dempsey JA. Effect of acute severe hypoxia on peripheral fatigue and endurance capacity in healthy humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R598-R606 (2007). (Pubitemid 46089876)
172. Caquelard F, Burnet H, Tagliarini F, Cauchy E, Richalet JP, Jammes Y. Effects of prolonged hypobaric hypoxia on human skeletal muscle function and electromyographic events. Clin. Sci. (Lond.) 98, 329-337 (2000). (Pubitemid 30145240)
173. Rafferty GF, Lou Harris M, Polkey MI, Greenough A, Moxham J. Effect of hypercapnia on maximal voluntary ventilation and diaphragm fatigue in normal humans. Am. J. Respir. Crit. Care Med. 160, 1567-1571 (1999).
174. Goldberg A, Goodman H. Relationship between cortisone and muscle work in determining muscle size. J. Physiol. 200, 667-675 (1969).
175. Kaminski HJ, Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands, and iatrogenic corticosteroid myopathy. In: Myology. Engel AG, Franzini-Armstrong C (Eds). McGraw-Hill Medical, New York, NY, USA, 1726-1733 (1994).
176. Nava S, Bruschi C, Franchia C, Fezicetti G, Callezsri G, Ambrosino N. Acute treatment with corsticosteroids (CS) alters respiratory (RM) and skeletal muscles (SM) function in humans. Eur. Respir. J. 9(Suppl.), S298 (1996) (Abstract).
177. Waclawik AJ, Sufit RL, Beinlich BR, Schutta HS. Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. Neuromuscul. Disord. 2, 19-26 (1992).
178. Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK. A syndrome of acute severe muscle necrosis in intensive care unit patients. J. Neuropathol. Exp. Neurol. 52, 387-398 (1993). (Pubitemid 23199199)
179. Decramer M, deBock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 153, 1958-1964 (1996). (Pubitemid 26187926)
180. Lieu F, Powers SK, Herb RA et al. Exercise and glucocorticoid-induced diaphragmatic myopathy. J. Appl. Physiol. 75, 763-771 (1993). (Pubitemid 23260219)
181. Qiu Z, Zhao D, Shi Y, Liu Y. [The effects of high dose atropine on function of isolated diaphragmatic preparation of rats with omethoate poisoning]. Zhonghua Nei Ke Za Zhi 40, 187-189 (2001).
182. Karataş GK, Günendi Z. Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation. NeuroRehabilitation 27, 141-145 (2010).
183. The Pharmacological Basis of Therapeutics. XI Edition. Brunton LL, Lazo JS, Parker KL (Eds). Goldman & Gilman's, McGraw-Hill, New York, NY, USA (2006).
184. Applied Therapeutics. IX Edition. Koda- Kimble MA, Young LY, Alldredge BK et al. (Eds). Lippincott Williams & Wilkins. PA, USA (2009).
185. Kaiser P, Hylander B, Eliasson K, Kaijer L. Effect of beta1-selective and nonselective beta blockade on blood pressure relative to physical performance in men with systemic hypertension. Am. J. Cardiol. 55, D79-D84 (1985).
186. Cupido CM, Hicks AL, McKelvie RS, Sale DG, McComas AJ. Effect of selective and nonselective beta-blockade on skeletal muscle excitability and fatigability. J. Appl. Physiol. 76, 2461-2466 (1994). (Pubitemid 24184766)
187. Nemirovskaia TL, Kitina IuN, Zgelesniakova AV, Vikhliandtsev IM. [Cytoskeletal proteins and heat shock proteins 27 under eccentric exercise of rats: Effects of calcium L-type channel blockade]. Ross. Fiziol . Zh. Im. IM Sechenova 94, 293-300 (2008).
188. Porter GA Jr, Makuck RF, Rivkees SA. Reduction in intracellular calcium levels inhibits myoblast differentiation. J. Biol. Chem. 277, 28942-28947 (2002).
189. Mahajan H, Richards SM, Rattigan S, Clark MG. T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo. Br. J. Pharmacol. 140, 1283-1291 (2003). (Pubitemid 38117433)
190. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2, e806 (2007).
191. Celli BR, MacNee W, and committee members. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932-946 (2004). (Pubitemid 38807371)
192. American Association for Cardiovascular and Pulmonary Rehabilitation. Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs. 4th Edition. Human Kinetics Publishers, Champaign, IL, USA (2004).
193. Salman GF, Mosier MC, Beasley BW, Clakins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: Meta-analysis of randomized controlled trials. J. Gen. Intern. Med. 18, 213-221 (2003). (Pubitemid 36399459)
194. Ramírez-Sarmiento A, Orozco-Levi M, Güell R et al. Inspiratory muscle training in patients with chronic obstructive pulmonary disease: Structural adaptation and physiologic outcomes. Am. J. Respir. Crit. Care Med. 166, 1491-1497 (2002). (Pubitemid 35387300)
195. Wijkstra PJ. Non-invasive positive pressure ventilation (NIPPV) in stable patients with chronic obstructive pulmonary disease (COPD). Respir. Med. 97, 1086-1093 (2003). (Pubitemid 37185111)
196. Svartberg J. Androgens and chronic obstructive pulmonary disease. Curr. Opin. Endocrinol. Diabetes Obes. 17, 257-261 (2010).
197. Schols AM. Nutritional modulation as part of the integrated management of chronic obstructive pulmonary disease. Proc. Nutr. Soc. 62, 783-791 (2003). (Pubitemid 38004973)
198. Casaburi R, Bhasin S, Cosentino L et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 870-878 (2004). (Pubitemid 39346482)
199. Goldspink G. Research on mechano growth factor: Its potential for optimising physical training as well as misuse in doping. Br. J. Sports Med. 39, 787-788 (2005). (Pubitemid 41564909)
200. Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr. Opin. Drug Discov. Devel. 11, 487-494 (2008). (Pubitemid 351950844)
201. Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol. (Berl.) 105, 217-224 (2003). (Pubitemid 36798812)
202. Warren GL, Hulderman T, Jensen N et al. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J. 16, 1630-1632 (2002).
203. Supinski GS, Stofan D, Ciufo R, DiMarco A. N-acetylcysteine administration alters the response to inspiratory loading in oxygen-supplemented rats. J. Appl. Physiol. 82, 1119-1125 (1997). (Pubitemid 27172313)
204. Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur. Respir. J. 34(Suppl.), S67-S77 (2001).
205. Maggio M, Ceda GP, Lauretani F et al. Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects of 65 years of age (the InCHIANTI study). Am. J. Cardiol. 97, 1525-1529 (2006).
206. Coirault C, Hagege A, Chemla D, Fratacci MD, Guerot C, Lecarpentier Y. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. Chest 119, 1755-1760 (2001). (Pubitemid 32744933)
207. Doorduin J, Sinderby CA, Beck J et al. The calcium sensitizer levosimendan improves human diaphragm function. Am. J. Respir. Crit. Care Med. doi:201107-1268OCv1 (2011) (Epub ahead of print).
208. Estenne M. Effect of lung transplant and volume reduction surgery on respiratory muscle function. J. Appl. Physiol. 107, 977-986 (2009).
209. Emery MJ, Eveland RL, Eveland K, Couetil LL, Hildebrandt J, Swenson ER. Lung volume reduction by bronchoscopic administration of steam. Am. J. Respir. Crit. Care Med. 182, 1282-1291 (2010).